Biocon receives CRL for anti cancer drug, from USFDA
As per Biocon, the US health regulator has issued complete response letter (CRL) for proposed biosimilar Pegfilgrastim, which is to be used in treatment for...
Use UNICORN Signals App
By EquityPandit
